Skip to main content
Menu

Diabetes and Obesity

A DPP-IV Compound Makes It Through

After talking the other week about the problems that Takeda has had with their DPP-IV inhibitor for diabetes, it now appears that AstraZeneca and Bristol-Myers Squibb have made it through the same narrows with their own drug. Saxagliptin has met the FDA’s latest guidelines for cardiovascular safety, which (you’d think) will remove the biggest potential barrier to approval. The advisory committee is meeting today, so we’ll see how their vote goes.

10 comments on “A DPP-IV Compound Makes It Through”

  1. peej says:

    Looks like Novo’s compound -Liraglutide – might be in trouble though. Thyroid cancer and borderline CV data.
    Saxagliptin looks good at this point, but who knows what the reviewers will say. Ad committee is actually Wednesday, with liraglutide meeting on Thursday.

  2. Brian Orelli says:

    I don’t know. The FDA usually frowns on post-hoc analysis. (Ironic since that’s how Avandia’s heart problems were found). The advisory panel is actually tomorrow (4/1).

  3. mike says:

    did any of you guys nothe the similarity between galvus and the saxagliptin?Novartis needs some new patent guyz////

  4. Damien says:

    These new FDA rules have had a profound affect on the attractivness of diabetes as an indication for small spin out companies, its realy knocking the risk profile of the indication. I see the current drugs are continuing the pathway to development, but it will be interesting to see the effect it has on investors in the area, are big Pharma the only ones who are going to play in this field.
    Damien Bove (www.damienbove.com)

  5. MedChemMan says:

    Though both saxagliptin and vildagliptin belong to the cyanopyrrolidine class of compounds, saxagliptin has shown better efficacy over vildagliptin (5 mg vs. 50 mg?) in the clinical trails. Hence, it is the dose that makes saxagliptin more safe and well-tolerated. However, I suspect that both saxagliptin and vildagliptin have only moderate-to-low selectivity against DASH enzymes, DPP8 & DPP9.

  6. Anonymous BMS Researcher says:

    Today, 1 April 2009, the FDA Advisory Committee voted 10 to 2 that the CV risk data for saxagliptan were sufficient to rule out unacceptable cardiovascular risk relative to comparators in the program.

  7. Ex AstraZeneca Scientist says:

    What slice of the pie will AZ take from this deal? 50:50?

  8. Dr. Jo Jain says:

    Both Novartis and Merck have DPP+Metformin Combos. What about Controlled Release Metformin+ Januvia/Galvus combos? My Endocrinologist says it would be helpful

  9. Anonymous Former NVS Marketer says:

    Galvus + Metformin = Eucreas. Only in EU. Beware of skin tox. Among others.

  10. P.C.Shah says:

    Janivia+Metformin available now in India too

Comments are closed.